Liquid Biopsies for Colorectal Cancer Screening: 2021 Update

article image

The companies vying for leadership in blood-based colorectal cancer screening seem poised for a particularly eventful year, as data emerges on their tests almost simultaneously with finalization of a CMS NCD that seems likely to secure reimbursement for high-performing assays.

2020 was a breakout year for the liquid biopsy field and liquid biopsy manufacturers are indicating that this year will be even more important for making progress on both clinical evidence and commercialization.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: